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activation of type I receptors and downstream regulators. Nicousamide is a 1.1 class of drug, which
can inhibit renal ﬁbrosis in animal models of diabetic nephropathy. After cloning and puriﬁcation
of TGF-b RII, an in vitro substrate phosphorylation assay was set up to investigate the ability of
nicousamide to inhibit phosphorylation and formation of cellular downstream proteins. Our results
validate nicousamide as a potent inhibitor of phosphorylation of TGF-b RII.
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An increasing population of patients with diabetic nephro-
pathy is contributing greatly to the increasing prevalence of
chronic kidney disease1. This is because diabetic nephropathy
leads to gradual scarring of the tubulointerstitial region2.
Subsequently tubulointerstitial changes, such as ﬁbrosis,
appear to play a critical role in the progression of diabetic
nephropathy to kidney failure in patients with type-1 diabetes
and may play an even more important role in the progression
in patients with type-2 diabetes3.
Many drugs have been used to treat diabetic nephropathy,
including angiotensin II receptor antagonists, such as losartan
and irbesartan, and angiotensin converting enzyme inhibitors,
such as captopril and benazepril4–6. Many reports reveal that
drugs, which inhibit TGF-b are effective in the treatment of
chronic renal failure and in delaying the progress of end-stage
renal disease. TGF-b receptor II (TGF-b RII) plays a crucial
role in activation of the TGF-b pathway such that its
inhibition or modiﬁcation represents a promising therapeutic
strategy to inhibit renal ﬁbrosis.
TGF-b1 is known to be involved in renal ﬁbrogenesis,
which potentially leads to diabetic nephropathy. The TGF-b1
membrane receptor complex consists of two families of
proteins with serine–threonine kinase activity, namely TGF-b
RII and TGF-b RI. TGF-b1 activates its receptors through a
combination of two pathways. In the ﬁrst pathway, TGF-b1
combines with TGF-b RIII and then transfers to TGF-b RII; in
the second pathway, TGF-b1 combines directly with TGF-b
RII. The two pathways ultimately lead to phosphorylation of
TGF-b RII after its activation to a (TGF-b1)–(TGF-b RII)
complex. The complex recruits and phosphorylates TGF-b RI
after which phosphorylated TGF-b RI continues to phosphor-
ylate its downstream functional proteins, Smad2, Smad3, etc.
Phosphorylation of Smad2 and Smad3 leads to their transloca-
tion into the nucleus and subsequently to tissue ﬁbrosis7–9.
TGF-b RII plays a key role during phosphorylation and
activation of TGF-b RI receptors and Smad transcriptional
regulators. In the absence of TGF-b RII, TGF-b has no
afﬁnity for TGF-b RI. Therefore, inhibiting the phosphoryla-
tion of TGF-b1 and its receptors is one way to prevent renal
ﬁbrosis. Kushibiki et al.10 showed that blocking the expression
of TGF-b RII by RNA interference could inhibit renal
ﬁbrosis. Kasuga et al.11 explored the effects of human
monoclonal antibody against TGF-b RII on experimental
proliferative glomerulonephritis and found that anti-TGF-b
RII antibody ameliorates ECM accumulation, which is a
common histopathological feature during renal ﬁbrosis.
Nicousamide (Fig. 1) is a class 1.1 drug protected by
domestic and international patents and currently undergoing
a phase I clinical trial in diabetic nephropathy. Studies in rat
models of 5/6 nephrectomy and streptozotocin (STZ) induced
diabetic nephropathy have shown that nicousamide can
alleviate renal failure and reduce glomerulosclerosis andFigure 1 Chemical structure of nicousamide (C18H12N2O9 H2O).interstitial ﬁbrosis by inhibiting renin and phosphorylation of
TGF-b RII. In this respect it is better than benazepril and
equipotent with losartan (manuscript in preparation). To
validate the cellular mechanism by which nicousamide protects
against diabetic nephropathy, we cloned the kinase domain of
TGF-b RII and puriﬁed TGF-b RII protein with autopho-
sphorylation ability. Subsequently we investigated the ability of
nicousamide to inhibit the phosphorylation of TGF-b RII and
its effect on cellular downstream proteins in an in vitro substrate
phosphorylation assay.2. Materials and methods
2.1. Nicousamide
Nicousamide was provided by the Laboratory of Chemical
Synthesis, Institute of Materia Medica, Chinese Academy of
Medical Sciences. Nicousamide is a novel compound ﬁrst
synthesized by the Department of Medicinal Chemistry,
Institute of Materia Medica (Beijing, China). Its structure
and purity were conﬁrmed by X-ray diffraction, NMR,
infrared and mass spectroscopy and by HPLC-UV12.
2.2. Enzymes and antibodies
EcoRI and XhoI enzymes were obtained from Takara Bio Inc.
Human TGF-b1 was purchased from R&D systems. Rabbit
polyclonal antibody against TGF-b RII, phosphor-TGF-b
RII, Smad2/3, phosphor-Smad and PY20 were purchased
from Cell Signaling Technology. Mouse monoclonal anti-
phosphothreonine antibody was purchased from Santa Cruz
Biotechnology. Glutathione sepharose 4B was from GE.
TGF-b RI Kinase Inhibitor II (ALK5 Inhibitor II) was
purchased from Calbiochem.
2.3. Cell culture
HK-2 (human renal proximal tubular epithelial) cells were
cultured in Dulbecco’s modiﬁed Eagle’s medium containing
10% FBS in 5% CO2 atmosphere at 37 1C.
2.4. GST fusion constructs and R2 protein puriﬁcation
To generate the GST-R2 fusion protein, the cytoplasmic
domain of TGF-b RII was ampliﬁed by PCR from RNA of
HK-2 using forward (50-GGAATTCCGGCAGCAGAAGCT-
GAG-30) and reverse (50-CCGCTCGAGCTATTTGGTAG-
TGTTTAG-30) primers, and the product was cloned into
pGEX 4T-1 vector, i.e. GST-R2. The GST-R2 clone was
identiﬁed by double enzyme digestion (EcoRI and XhoI) and
gene sequencing.
Human recombinant protein GST-R2 was induced and then
puriﬁed by glutathione sepharose 4B. Brieﬂy, GST-R2 protein
expression was induced by the addition of 0.25 mmol/L
isopropyl-D-thiogalactopyranoside (IPTG) until the BL21
culture reached an OD600 of approximately 0.5. After induc-
tion for 4–18 h at 16 1C, cells were collected by centrifugation
at 6000 g for 10 min and frozen. After thawing, the cells
were suspended in NETN buffer (20 mmol/L Tris–HCl pH
7.4, 100 mmol/L NaCl, 5 mmol/L EDTA and 0.5% NP40).
Figure 2 The cytoplasmic domain of TGF-b RII cloned into
pGEX 4T-1 vector i.e. GST-R2. The GST-R2 clone was digested
by double enzyme (EcoRI and XhoI) and the digestion fragments
separated on 1.5% sepharose. The digestion fragments (lane 1)
were pGEX 4T-1 (4969 bp) and the cytoplasmic domain of TGF-b
RII (1119 bp).
Hai-jing Zhang et al.162After gentle sonication of the lysates, cell debris and larger
particles were removed by centrifugation at 10,000 g for
20 min and the supernatant ﬁltered through a 0.45-mm ﬁlter.
The supernatant was then applied to a glutathione sepharose
4B column, pre-equilibrated with NETN buffer. The column
was washed with loading buffer to remove non-speciﬁcally
bound proteins after which the recombinant protein was
eluted with 2 column volumes of 50 mmol/L Tris–HCl (pH
8.0) containing 10 mmol/L glutathione. The eluted fraction
was immediately aliquoted and stored at 20 1C until further
use. Puriﬁed GST-R2 protein was analyzed by 10% SDS/
PAGE using Coomassie brilliant blue R staining and identiﬁed
by mass spectrometry.
2.5. In-gel digestion and identiﬁcation by mass spectrometry
The excised gel of puriﬁed GST-R2 protein was cut into pieces
and washed in doubly distilled water. Acetonitrile was added
to dehydrate the gel pieces after which the dried gels were
reduced by incubation with 50 mL of 10 mmol/L dithiothreitol
in 25 mmol/L NH4HCO3 at 57 1C for 1 h. Alkylation was then
carried out by adding 50 mL of 20 mmol/L iodoacetamide in
25 mmol/L NH4HCO3 and maintaining at room temperature
in the dark for 45 min. After removing excess reduction buffer,
the gel pieces were washed twice with 500 mL doubly distilled
water, dehydrated again with acetonitrile and incubated in
trypsin (5 ng/mL) dissolved in 25 mmol/L NH4HCO3 on ice
for 1 h and then at 37 1C for another 12 h. The supernatant
from the digestion was analyzed by MALDI MS as follows.
Lyophilized samples were spotted on a MALDI target in a
CHCA matrix (10 mg/mL in 50% acetonitrile) and analyzed
in a 4700 MALDI TOF/TOFTM Analyzer (Applied Biosys-
tems, CA) equipped with a Nd:YAG 355 nm laser. The
instrument was operated in the positive ion mode and MS/
MS acquisitions in the 900–3500 mass range were acquired
using a laser repetition rate of 200 Hz. A collision energy
of 2 kV (with CID gas off) was used to fragment the peptides
and MS/MS spectra were calibrated with angiotensin
(m/z 1296.6853), Glu-ﬁbrinopeptide B (m/z 1570.6774), ACTH
1–17 (m/z 2093.0186) and ACTH 18–39 (m/z 2465.1989).
Database searches for protein identiﬁcation were performed
using MASCOT. Trypsin was used in this search. Both MS
and MS/MS tolerance was 0.2 Da. Data were further
processed using Data Explorer 4.5 (Applied Biosystems,
Framingham, MA).
2.6. In vitro substrate phosphorylation by GST-R2 and its
inhibition by nicousamide
The kinase speciﬁcity of the TGF-b RII cytoplasmic domain was
tested using exogenous substrate and nicousamide. GST-R2
fusion protein (2 mg) in 40 mL kinase buffer (25 mmol/L
HEPES pH 7.4, 10 mmol/L MnCl2, 10 mmol/L MgCl2, and
10 mmol/L ATP) was used in the phosphorylation assay.
Kinase reactions were carried out for 20 min at 25 1C. When
appropriate, histone 2B was added as substrate at a ﬁnal
concentration of 100 ng/mL and nicousamide was also added
as an inhibitor at concentrations of 0.01 and 0.1 mmol/L.
Kinase reactions were terminated by addition of an equal
volume of sample buffer after which samples were boiled for
5 min prior to separation by SDS-PAGE. Mouse monoclonalPY20 and anti-phosphothreonine antibodies were used to
detect phosphorylated tyrosine residues of GST-R2 fusion
protein and histone 2B, respectively.
2.7. Immunoblotting analysis
HK-2 cells were serum-starved for 12 h and treated with
recombinant TGF-b1 (5 ng/mL) in the presence of nicousa-
mide for 15, 30, 60, 120 and 240 min. Cells were washed three
times with cold phosphate buffered saline (PBS) before
preparation of cell lysates for immunoblot analysis. Cells were
subsequently detached by scraping into 1 mL cold PBS. After
centrifugation at 3000 rpm for 10 min, cell pellets were
solubilized in lysis buffer for 2 h. Samples were centrifuged
at 10,000 rpm for 20 min after which the supernatant was
analysed using the Bradford assay and then stored at 80 1C
until use. Proteins were analyzed by Western-blot with anti–
R2, anti-phospho–R2, anti-phospho-Smad2/3, Smad2/3 and
anti-b-actin antibodies.3. Results
3.1. GST-R2 cloning and puriﬁcation
The cytoplasmic domain of TGF-b RII was ampliﬁed by PCR
from the RNA of HK-2 cells and cloned into pGEX 4T-1
vector, i.e. GST-R2. The digestions of the GST-R2 clone by
EcoRI and XhoI were separated on 1.5% agarose gel. The
results are shown in Fig. 2. Lane 1 shows the digestion
fragments which include the pGEX 4T-1 vector (4969 bp)
and the cytoplasmic domain of TGF-b RII (1119 bp). The
recombinant protein GST-R2 was then induced using
0.25 mmol/L IPTG for different periods of time and puriﬁed
on Sepharose 4B. The results of 10% SDS/PAGE of cell
lysates and puriﬁed GST-R2 protein are shown in Fig. 3. The
cytoplasmic domain of TGF-b RII is clearly seen in lane 4.
3.2. Identiﬁcation of puriﬁed GST-R2 protein
The mass spectrum and an MS/MS spectrum of GST-R2 are
shown in Fig. 4A. The detailed results of a Mascot search are
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puriﬁed protein is indeed the intracellular kinase domain of
TGF-b RII.Figure 3 Expression and puriﬁcation of TGF-b RII. Expression
of TGF-b R II was induced by 0.25 mmol/L IPTG for 4 or 18 h at
16 1C. Cell lysate supernatants were enriched on a glutathione
sepharose 4B column and puriﬁed GST-R2 protein was analyzed
by 10% SDS/PAGE. Marker was a protein marker; lane 1 was
lysate of vector; lanes 2 and 3 were, respectively, cell lysate
supernatant from the GST-R2 clone induced by IPTG for 4 and
18 h; lane 4 was puriﬁed protein eluted from sepharose 4B.
Figure 4 Identiﬁcation of puriﬁed GST-R2 protein by mass spectrom
MS and MS/MS. (A) MS and MS/MS spectra of the GST-R2 diges
1145.52 with continuously y series ions marked out. (B) Mascot search
database. The underlined parts represent peptides matched with theor
high coverage (51%) verify that the cloned and puriﬁed protein is the3.3. In vitro substrate phosphorylation by GST-R2 and its
inhibition by nicousamide
After characterization of the puriﬁed GST-R2 protein, an
in vitro substrate phosphorylation assay was used to detect its
kinase activity and the ability of nicousamide to inhibit it.
Fig. 5 displays the Western-blot results with the anti-phos-
phorylate antibodies, anti-p-Tyr (PY20) and anti-p-Ser. The
results show that nicousamide can inhibit the phosphorylation
activity of TGF-b RII on histone 2B. Quantitation using
Image J software reveals that 1 mmol/L nicousamide inhibits
50% of the phosphorylation activity of TGF-b RII.
3.4. Inhibition by nicousamide of phosphorylation of
downstream proteins
The ability of nicousamide to inhibit the phosphorylation of
downstream proteins was studied in HK-2 cells. HK-2 cellsetry. The supernatant from the digestion was analyzed by MALDI
tion. The insert is the MS/MS spectrum of the fragment at m/z
results of the GST-R2 MS and MS/MS spectra in the Swiss-Prot
etical sequences. The search results including high score (354) and
intracellular kinase domain of TGF-b RII.
Figure 5 Kinase activity of puriﬁed GST-R2 protein and inhibition of kinase activity by nicousamide in the in vitro substrate
phosphorylation assay. The kinase speciﬁcity of the TGF-b RII cytoplasmic domain was tested using the anti-phosphorylate antibodies,
anti-p-Tyr (PY20) and anti-p-Ser. Puriﬁed GST-R2 protein was added to all samples. Lane 1 is control 1 without ATP and nicousamide;
lane 2 is control 2 without nicousamide; lanes 3 and 4 are samples containing 0.1 and 1 mmol/L nicousamide, respectively. Quantitation
by Image J software is shown on the right. Black columns represent the results of anti-PY20, i.e. the phosphorylated tyrosine of histone
2B;Gray columns represent the results of anti-p-Ser, i.e. the phosphorylated serine of histone 2B.
Figure 6 HK-2 cells (serum-starved for 12 h) treated with recombinant TGF-b1 (5 ng/mL) for from 15 to 240 min. Proteins were
analyzed by Western-blot with anti-p-Smad and Smad. C is control without treatment. Quantitation of the results is shown on the right.
Figure 7 HK-2 cells (serum-starved for 12 h) treated with recombinant TGF-b1 (5 ng/mL) in the presence of nicousamide for 1 h.
Proteins were analyzed by Western-blot with anti-p-Smad2/3, Smad2/3 and anti-b-actin antibodies. Quantitation of the results by Image J
software (shown of the right) shows 10 mmol/L nicousamide effectively inhibits the expression of p-Smad. C and TLK are negative and
positive controls, respectively.
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binant TGF-b1 (5 ng/mL) for 15, 30, 60, 120 and 240 min.
Western-blot results show that the phosphorylation of Smad2/3
(p-Smad2/3) reached a maximum at 60 min (Fig. 6). A duration
of 60 min was therefore chosen for subsequent TGF-b1
treatment.
Cells were lysed and analyzed by Western-blot with anti-
phospho-Smad2/3 and Smad2/3 (Fig. 7). Nicousamide was
found to inhibit phosphorylation of Smad (p-Smad) efﬁciently.4. Discussion
TGF-b RII is a 567 amino acid transmembrane glycoprotein
containing a 136 residue TGF-b1 binding domain, a singletransmembrane region and an intracellular kinase domain.
TGF-b RII possesses a constitutively active serine/threonine
kinase in the cytoplasmic domain and can phosphorylate the
kinase domain of TGF-b RI, thereby initiating a signaling
cascade through the Smad pathways13. In this study, the
ability of nicousamide to inhibit phosphorylation of the
cytoplasmic domain of TGF-b RII was studied.
First the cytoplasmic domain of TGF-b RII was cloned,
puriﬁed and identiﬁed by enzyme digestion and mass spectro-
metry. Fig. 3 shows that the cytoplasmic domain of TGF-b
RII was puriﬁed (lane 4) and Fig. 4 illustrates that mass
spectrometry veriﬁed that the puriﬁed protein was the cyto-
plasmic domain of TGF-b RII. Fig. 4B shows the complete
amino acid sequence of TGF-b R II and the matched peptides.
The Mascot search found TGF-beta receptor type-2 precursor
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value 5.60. The gray part of Fig. 4B representing peptides
matched with the theoretical sequence indicates that coverage
of identiﬁed peptides reached 51%. The matched peptides
mainly cover the theoretical cytoplasmic domain of TGF-b
RII (from 192 to 565 amino acids), which validates that only
the cytoplasmic domain was expressed and puriﬁed. The
results taken together provide adequate proof that the cyto-
plasmic domain of TGF-b R II was successfully puriﬁed.
Previous studies have shown that autophosphorylation of
tyrosine or serine residues is associated with activation of
protein kinase activity toward exogenous protein sub-
strates14,15. In addition, it has been shown that an in vitro
substrate phosphorylation assay can be used to deﬁne the
relationship between receptor autophosphorylation and acti-
vation of the autophosphorylated receptor kinase by small
molecular weight inhibitors. To verify the kinase activity of
puriﬁed R2 protein and the ability of nicousamide to inhibit
kinase activity, an in vitro substrate phosphorylation assay was
utilized. The Western-blot results with anti-p-TGF-b RII show
that puriﬁed R2 protein possesses autophosphorylation activ-
ity (Fig. 5). Subsequently nicousamide was shown to inhibit
50% of the phosphorylation activity of TGF-b RII at a
concentration of 1 mmol/L. This result clearly shows that
nicousamide is an effective inhibitor of the phosphorylation
activity of TGF-b RII.
In further studies, the inhibiting effect of nicousamide was
determined in HK-2 cells. These human renal proximal
tubular epithelial cells have been commonly used to investigate
the etiology of renal disease including the stimulation of renal
ﬁbrosis by TGF-b116,17.
In the absence of a TGF-b RII inhibitor to act as positive
control, ALK5 inhibitor II, a TGF-b1 inhibitor, known to
inhibit common downstream Smad proteins18–20 was used.
After treatment of HK-2 cells with recombinant TGF-b1
(5 ng/mL) in the presence of nicousamide, it was found that
nicousamide inhibited the phosphorylation of Smad by 50%
at a concentration of 10 mmol/L (Fig. 7). The results validate
nicousamide as an effective inhibitor of the TGF-b1 pathway
by inhibiting phosphorylation of TGF-b RII. On this basis, it
appears that nicousamide has the potential to inhibit ﬁbrosis
induced by the TGF-b–TGF-b RII pathway.
In summary, the intracellular kinase domain of TGF-b RII
has been cloned, puriﬁed and its identity conﬁrmed by enzyme
digestion and mass spectrometry. Subsequently the ability of
nicousamide to inhibit the phosphorylation activity of TGF-b
RII was investigated in an in vitro substrate phosphorylation
assay. The ability of nicousamide to inhibit the formation of
Smad proteins was also investigated in HK-2 cells. All results
validate nicousamide as a potent inhibitor of the TGF-b1
pathway via inhibition of phosphorylation of TGF-b RII.Acknowledgment
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